Small molecule could slow or stop progress of Parkinson's disease and related brain disorders, not just treat symptoms

A team of researchers from NYU Abu Dhabi and the University of Denver has identified a promising small molecule that could ...
Seeking Alpha

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

- Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders - The posters presented from Alterity’s bioMUSE study address the need for incorporating biomarkers as a ...
technologynetworks

Method Can Distinguish Parkinson's Disease From Multiple System Atrophy

Scientists have found a way to distinguish between two progressive neurodegenerative diseases, Parkinson’s disease (PD) and multiple system atrophy (MSA), using a technology developed by a researcher ...
PharmiWeb

Multiple System Atrophy Therapeutics Market Growth Outlook to 2033: Size, Share, Trends, and Emerging Therapies

Multiple System Atrophy (MSA) is a progressive, rare neurodegenerative disorder adversely affecting the autonomic nervous system, movement, balance, coordination, and various bodily functions.
Yahoo Finance

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

MELBOURNE, Australia and SAN FRANCISCO, March 02, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
PharmiWeb

Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy

MASCOT, a global phase III randomized, double-blind, placebo-controlled trial, will assess the efficacy and safety of amlenetug in the treatment of Multiple System Atrophy (MSA) H. Lundbeck A/S ...